Skip to main content
Premium Trial:

Request an Annual Quote

Proteome Sciences Signs Contract with Takeda for Protein Biomarker Research


This story originally ran on March 30.

Proteome Sciences said this week it has closed a second research contract with drugmaker Takeda Pharmaceuticals for use of the company's PS Biomarker Services.

Under the agreement, Proteome Sciences will provide Takeda with mass spec-based assays for the discovery and validation of protein biomarkers tied to various undisclosed diseases.

The contract follows on a 2009 agreement between the companies, under which Proteome Sciences has used its isobaric Tandem Mass Tag reagents for preclinical protein biomarker research.

The deal is the latest of several contracts for pharma work the company has signed in recent months.

In February it announced that had signed with drugmaker Eisai to measure protein biomarkers tied to Alzheimer's disease (PM 02/04/2011). That contract called for Proteome Sciences to quantify in human samples levels of the nine proteins in its AD-TMT-SRM assay, marking the first commercial contract the company signed for use of the assay, which it introduced this summer.

In November it inked a deal with Irish pharmaceutical services firm Icon to offer biomarker discovery and validation work in support of drug development efforts (PM 11/19/2010).

Financial and other terms of the Takeda agreement were not disclosed.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.